Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate Relapse Prevention in Schizoaffective Disorder
NCT01193153Phase 3Completed
- Sponsor
- Janssen Scientific Affairs
- Start
- Sep 2010
- Primary completion
- Oct 2013
- Modality
- Metabolically Activated Prodrugs
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in schizoaffective disorder comparing Paliperidone Palmitate with Placebo (2 arms). Primary endpoint: Percentage of Participants Who Experienced Relapse at 15 months. Started Sep 2010; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizoaffective disorder
Beyond the preview
Go deeper on NCT01193153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01193153.